Therapeutic area
Neurology
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
19
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
127
Industry-sponsored
Recruiting Phase 3
103
Industry-sponsored
Recruiting Phase 4 (post-approval)
13
Industry-sponsored
Recent approvals
- Klygefa (Gefurulimab) · Alexion Pharm NovelOrphanNov 13, 2026
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
- Juvmo (Tavapadon) · Abbvie NovelSep 25, 2026
To treat Parkinson's disease in adults
- Isembyld (Apitegromab-Mstn) · Scholar Rock INC NovelPriority reviewOrphanSep 11, 2026
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
- Tauklarify (Florquinitau F-18) · Cerveau Lantheus NovelAug 13, 2026
To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology
- Orzeyful (Oveporexton) · Takeda Pharms USA NovelPriority reviewOrphanAug 5, 2026
To treat narcolepsy type 1
- Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc. NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanMar 24, 2026
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Subvenite (Lamotrigine) · Owp Pharms Sep 16, 2025
- Imaavy (Nipocalimab-Aahu) · Janssen Biotech NovelPriority reviewOrphanApr 29, 2025
To treat generalized myasthenia gravis
- Kisunla (Donanemab-Azbt) · Eli Lilly CO NovelBreakthrough therapyPriority reviewJul 2, 2024
To treat Alzheimer's disease
- Vigafyde (Vigabatrin) · Pyros Pharms OrphanJun 17, 2024
- Duvyzat (Givinostat Hydrochloride) · Italfarmaco Spa NovelPriority reviewOrphanMar 21, 2024
To treat Duchenne muscular dystrophy in individuals aged 6 years and older
- Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca Ab NovelOrphanDec 21, 2023
To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
- Agamree (Vamorolone) · Catalyst Pharms NovelOrphanOct 26, 2023
To treat Duchenne muscular dystrophy
- Zilbrysq (Zilucoplan Sodium) · Ucb INC NovelOrphanOct 17, 2023
To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive
- Rystiggo (Rozanolixizumab-Noli) · Ucb INC NovelPriority reviewOrphanJun 26, 2023
To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
- UCB2
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- OrelabrutinibICP-022Phase 311 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- EmpasiprubartARGX-117Phase 39 trials
argenx · Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- ALKS 2680AlixorextonPhase 37 trials
Alkermes, Inc. · Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
- CorabotaseIPN10200Phase 37 trials
Ipsen · Moderate to Severe Glabellar Lines, Spasticity, Moderate to Severe Upper Facial Lines
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- FenebrutinibRO7010939, GDC-0853Phase 36 trials
Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
Largest recruiting Phase 3 trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- Randomized Study in Children and Adolescents With Migraine: Acute TreatmentPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT04649242 · 2,100 participants (planned) · Start Jan 15, 2021 · Primary completion Jan 9, 2029
Drug: Rimegepant/BHV3000; Matching placebo · For: Pediatric Migraine
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tempe, Arizona · 246 sites in all
- Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in AdultsPivotal-lookingRecruiting
Brise Pharmaceuticals Co., Ltd.Industry
NCT07792681 · 2,079 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2028
Drug: BR005-036C; BR005-036C and 1 more · For: Migraine, With or Without Aura
Sites: Shanxi, China; Inner Mongolia, China; Beijing, China · 81 sites in all
- A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePivotal-lookingRecruiting
TriGemX Bio, Inc.Industry
NCT07645924 · 1,800 participants (planned) · Start Jul 1, 2026 · Primary completion Feb 2027
Drug: Elismetrep; Placebo · For: Migraine
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 113 sites in all
- A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07717411 · 1,600 participants (planned) · Start Oct 2, 2026 · Primary completion Jul 30, 2032
Drug: Trontinemab; Placebo · For: Alzheimer's Disease
Sites: Irvine, California; Long Beach, California; Los Angeles, California · 72 sites in all
- A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePivotal-lookingRecruiting
TriGemX Bio, Inc.Industry
NCT07816367 · 1,500 participants (planned) · Start Oct 2, 2026 · Primary completion Oct 2027
Drug: Elismetrep; Placebo · For: Migraine
Sites: Glendale, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 72 sites in all
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07225504 · 1,275 participants (planned) · Start Nov 11, 2025 · Primary completion Dec 3, 2030
Drug: Remibrutinib (blinded); Placebo and 1 more · For: Secondary Progressive Multiple Sclerosis (SPMS)
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 296 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06312176 · 1,200 participants (planned) · Start Apr 14, 2024 · Primary completion Jul 11, 2027
Drug: Sacituzumab tirumotecan; Pembrolizumab and 4 more · For: Breast Neoplasms
Sites: Chandler, Arizona; Gilbert, Arizona; Fullerton, California · 259 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06952504 · 1,123 participants (planned) · Start May 22, 2025 · Primary completion May 24, 2032
Drug: Pembrolizumab; Carboplatin and 4 more · For: Endometrial Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Irvine, California · 272 sites in all
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06628908 · 1,100 participants (planned) · Start Oct 1, 2024 · Primary completion May 31, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Birmingham, Alabama; Daphne, Alabama · 76 sites in all
More: Neurology news · literature
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.